U.S. Markets closed

Atossa Therapeutics, Inc. (ATOS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.4800-0.0300 (-1.99%)
At close: 4:00PM EST

1.4800 0.00 (0.00%)
After hours: 7:17PM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.5100
Bid1.4800 x 3100
Ask1.5000 x 4000
Day's Range1.4700 - 1.5400
52 Week Range0.7600 - 5.0800
Avg. Volume229,101
Market Cap15.529M
Beta (5Y Monthly)2.54
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Atossa Stock at $8 a Share? This 5-Star Analyst Thinks It’s Possible

    Atossa Stock at $8 a Share? This 5-Star Analyst Thinks It’s Possible

    Shares of Atossa Therapeutics (ATOS) have done what shares of most companies in the hunt for coronavirus solutions have done in 2020 – appreciate. Since the turn of the year, there has been 171% of upside for the Seattle-based biotech firm.Despite the impressive gains, the micro-cap still has a market cap of only $39 million. Going by his revised outlook for Atossa, Maxim’s 5-star analyst Jason McCarthy believes the stock remains seriously undervalued.McCarthy recently doubled his price target from $4 to $8. The implication for investors? Upside of a very hefty 119%. There’s no change to McCarthy’s rating, which remains a Buy. (To watch McCarthy’s track record, click here)Along with the company’s core breast cancer and mammographic breast density programs, McCarthy adds recent developments in Atossa’s battle against COVID-19 as possible catalysts to drive shares even higher.Atossa already has one COVID-19 treatment in development – AT-H201 (HOPE), for which it announced positive in vitro data in May (the drug inhibited SARS-CoV-2 from infecting VERO cells in laboratory culture). Atossa is currently awaiting FDA and IRB (institutional review board) approval to move forward with the AT-H201 HOPE study.But last week, Atossa announcedpositive results from an in vitro study of another COVID-19 drug candidate, its nasal spray AT-301. As with AT-H201, preliminary data revealed that AT-301 successfully prevented SARS-CoV-2 infection of VERO cells.The company has now partnered with Australia based Avance Clinical, to go ahead with a clinical trial expected to begin this quarter.While AT-H201 focuses on severely ill patients who need mechanical ventilation, AT-301 is being developed for use in people who have yet to exhibit any symptoms but have been tested positive for COVID-19.Although it is still early days, McCarthy believes both treatments now merit inclusion in his Atossa model.The analyst said, “We have factored in both AT-H201 and AT-301 for COVID-19. Considering the early development stage of both assets and the uncertainty in the COVID-19 therapeutic environment, we apply a higher risk adjustment, 90%, for both AT-H201 and AT-301. Furthermore, we assume both AT-H201 and AT-301 could obtain EUA approval for healthcare workers in 2021 and 2022 respectively, followed by approval for the general population in 2022 and 2023.”While in the long term, neither treatment can probably replace the need for a vaccine, both can have a part to play until a viable solution is bought to market.“These candidates, while early stage,” McCarthy said, “Could offer a more near-term solution while progress continues to be made on the vaccine front by multiple companies. A vaccine for the general population could still be 12-18+ months away.”To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. More recent articles from Smarter Analyst: * Stimulus Should Keep Boeing Afloat, But This 5-Star Analyst Remains Sidelined * Zoom: Work from Home is Here to Stay, But This Analyst Says Hold Off * Adobe, IBM Partner On Hybrid Cloud For Banking, Healthcare Industries * Logitech Ramps Up Annual Profit Outlook As Q1 Income Leaps 75%

  • Is Atossa Therapeutics (NASDAQ:ATOS) In A Good Position To Deliver On Growth Plans?
    Simply Wall St.

    Is Atossa Therapeutics (NASDAQ:ATOS) In A Good Position To Deliver On Growth Plans?

    We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

  • Atossa Genetics Joins the Race to Find COVID-19 Treatment; Analyst Says ‘Buy’

    Atossa Genetics Joins the Race to Find COVID-19 Treatment; Analyst Says ‘Buy’

    The world’s focus has zeroed in on healthcare companies. Hardly a surprising turn of events in these pandemic driven times. The search for a treatment or vaccine for COVID-19 has thrust into the limelight a host of smaller operators, who otherwise would have most likely remained under the wider public’s radar. The latest to join the race for a viable treatment is nano-cap Atossa Genetics (ATOS).Last week, shares of Atossa shot up by 35% following a launch announcement of a drug development program for COVID-19, called COVID-19 HOPE (AT-H201).The program consists of a combination of two undisclosed drugs already approved by the FDA for other diseases. The goal is to develop a therapy which will reduce the amount of time COVID-19 patients are on ventilators by improving lung function. Due to the large number of COVID-19 patients needing mechanical ventilation, hospitals are facing ventilator shortages, an issue Atossa hopes to solve with its novel offering.The company has filed provisional patent applications for the treatment and plans to apply to the FDA for approval to begin a clinical study under the Coronavirus Treatment Acceleration Program.Performing similarly to how antibodies against the virus would after a patient is vaccinated or immune, the purpose of AT-H201 is to block the ability of the virus to enter the target cells by mimicking the function of the antibodies formed from a vaccine.Maxim’s Jason McCarthy applauds Atossa’s “differentiated approach.” The analyst reiterated a Buy on ATOS along with a $4 price target, which implies an impressive 90% should the analyst’s target be met over the next 12 months. (To watch McCarthy’s track record, click here)McCarthy said, “The COVID pandemic needs testing, therapeutics and a vaccine. In reality, an effective vaccine is likely 12-18+ months away, and that would still be incredibly fast, in our view… As such having adequate testing and therapeutics which can 'blunt' the pandemic is critical, and all options are on the table.” (See Atossa stock analysis on TipRanks) More recent articles from Smarter Analyst: * Microsoft Reveals 4 New Surface Products Including Release Date For $199 Earbuds * All Eyes on Uber, Lyft Ahead of Earnings; Top Analyst Says 'Buy' * U.S. Air Carriers Lose More Than $10 Billion a Month - Report * 2 "Strong Buy" Dividend Stocks Yielding at Least 10%